Moore, G.J.; Ridgway, H.; Kelaidonis, K.; Chasapis, C.T.; Ligielli, I.; Mavromoustakos, T.; Bojarska, J.; Matsoukas, J.M.
Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System. Molecules 2022, 27, 4854.
https://doi.org/10.3390/molecules27154854
AMA Style
Moore GJ, Ridgway H, Kelaidonis K, Chasapis CT, Ligielli I, Mavromoustakos T, Bojarska J, Matsoukas JM.
Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System. Molecules. 2022; 27(15):4854.
https://doi.org/10.3390/molecules27154854
Chicago/Turabian Style
Moore, Graham J., Harry Ridgway, Konstantinos Kelaidonis, Christos T. Chasapis, Irene Ligielli, Thomas Mavromoustakos, Joanna Bojarska, and John M. Matsoukas.
2022. "Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System" Molecules 27, no. 15: 4854.
https://doi.org/10.3390/molecules27154854
APA Style
Moore, G. J., Ridgway, H., Kelaidonis, K., Chasapis, C. T., Ligielli, I., Mavromoustakos, T., Bojarska, J., & Matsoukas, J. M.
(2022). Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System. Molecules, 27(15), 4854.
https://doi.org/10.3390/molecules27154854
